Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.

Key Points Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. Aclaris Therapeutics is preparing a ...

Copyright: © 2026 The Author(s). Published by Elsevier Ltd.

An intravitreal insert provides durable control of multiple retinal diseases, according to a presentation at Retina World ...

Livedoid vasculopathy was diagnosed. After treatment with tofacitinib combined with topical Hirudoid and Jinyin Peptide, the lesions healed. Livedoid vasculopathy (LV) is a rare, recurrent, and ...

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence ...

Deal gives Vyome entry into the fast-growing market for next-generation autoimmune and inflammatory disease drugs ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (?21.6 PPriova ...

1 University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Department of Rheumatology, Düsseldorf, Germany 2 University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine ...

Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, is a chronic immune-mediated inflammatory disorder with limited long-term therapeutic options. Proteolysis-targeting ...

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...